TCR2 Therapeutics (TCRR) Announces $125M Proposed Public Offering of Common Stock

TCR² Therapeutics Inc. (Nasdaq: TCRR) (“TCR²” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. TCR² also intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock. All of the shares in the proposed offering are to be sold by TCR². The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Goldman Sachs & Co. LLC, Jefferies, Piper Sandler and BMO Capital Markets are acting as joint book-running managers for the offering.

TCR² intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital and general corporate purposes.

You May Also Be Interested In

• Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
• Bessent at Charlotte Private Luncheon warns China AI win would 'negate all else', targets 80% compute share by 2028
• Jefferies Starts Solstice Advanced Materials Inc. (SOLS) at Buy